ABSTRACT
Introduction The immune response caused by Mycobacterium leprae is a risk factor for the development of oxidative stress (OS) in leprosy patients. This study aimed to assess OS in leprosy patients before the use of a multidrug therapy. Methods We evaluated the nitric oxide (NO) concentration; antioxidant capacity; levels of malondialdehyde, methemoglobin and reduced glutathione; and the activity of catalase and superoxide dismutase (SOD) in leprosy patients. Results We observed lower SOD activity in these leprosy patients; however, the NO levels and antioxidant capacity were increased. Conclusions The infectious process in response to M. leprae could primarily be responsible for the OS observed in these patients. .
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Antioxidants/physiology , Glutathione/blood , Leprosy/metabolism , Nitric Oxide/blood , Oxidative Stress/physiology , Case-Control Studies , Leprosy/drug therapy , Leprosy/physiopathology , Oxidation-Reduction/drug effectsABSTRACT
Objetivo: compreender como os antimaláricos utilizados contra o Plasmodium falciparum vêmatuando no decorrer do tempo enfatizando os casos de resistência. Método: feita uma revisão daquimioterapia utilizada contra essa espécie de plasmódio, relatando diversas pesquisas voltadas aresistência aos antigos tratamentos utilizados e o surgimento de novos esquemas terapêuticos.Considerações finais: Arteméter-Lumefantrina foi adotado como primeira linha de tratamento paramalária na África, levando o Ministério da Saúde do Brasil, em 2006, a implantar esta combinaçãonos estados da Amazônia legal que apresentam casos de malária falciparum resistente a terapiapadrão.
Objective: understand how antimalarials used against Plasmodium falciparum has been in thecourse of time emphasizing the cases of resistance. Method: a review of chemotherapy usedagainst this species of plasmodium, reporting several studies focused on resistance to oldertreatments and the emergence of new therapeutic regimens. Final Thoughts:Arteméter+Lumefantrine was adopted as first line treatment for malaria in Africa, prompting theMinistry of Health of Brazil, in 2006, to deploy this combination in the legal Amazonpresenting cases of falciparum malaria resistant to standard therapy.